The role of genomics and genotyping has occupied a primary position in the oncological scenario, leading to an era in which treatments are tailored to each patient’s genetic profile. This allows to lower the risks of drug-dependent adverse effects and, consequently, the overall healthcare costs. In parallel with this, new high-throughput platforms are spreading in the routine of clinical diagnostics, encouraged by the progressive lowering of their costs, the strong cost-effectiveness, and their high sensitivity/specificity. Despite this technological advance, an important issue is represented by the validation and quality check of these tests, since they have extremely high standards of sensitivity and specificity. With appropriate controls, these assays can represent a powerful tool in the hands of oncologists for the continuous improvement of standard care for oncologic patients.